BASIC PHARMACOKINETICS
-
Upload
tamara-burgess -
Category
Documents
-
view
72 -
download
10
description
Transcript of BASIC PHARMACOKINETICS
![Page 1: BASIC PHARMACOKINETICS](https://reader035.fdocuments.in/reader035/viewer/2022081503/5681358c550346895d9cf3bc/html5/thumbnails/1.jpg)
BASIC PHARMACOKINETICS
![Page 2: BASIC PHARMACOKINETICS](https://reader035.fdocuments.in/reader035/viewer/2022081503/5681358c550346895d9cf3bc/html5/thumbnails/2.jpg)
FATE OF DRUGS IN BODY
DRUG ADMINISTERED
INTENDED EFFECTS
(ABSORPED)
ENTER SYSTEMICCIRCULATION
REACH SITE OFACTIONDISTRIBUTED
METABOLISED
ELIMINATED
![Page 3: BASIC PHARMACOKINETICS](https://reader035.fdocuments.in/reader035/viewer/2022081503/5681358c550346895d9cf3bc/html5/thumbnails/3.jpg)
Pharmacokinetics and pharmacodynamics
• Pharmacokinetics is the study of how a drug reaches its target in the body and how it is affected on that journey, i.e; effect of the body on the drug. – the study of how is the drug absorbed,
distributed, metabolized and excreted in the body
• Pharmacodynamics is the study of how drugs interact with a molecular target, i.e; effect of the drug on the body.
3
![Page 4: BASIC PHARMACOKINETICS](https://reader035.fdocuments.in/reader035/viewer/2022081503/5681358c550346895d9cf3bc/html5/thumbnails/4.jpg)
ADMINISTRATION
• Aim of drugs administration is to achieve therapeutic level at site of action.
• Route of drugs administration : First category – drugs must pass
through a barrier to reach systemic circulation.1. Oral
2. Inhalational3. Injection into the body but not the vascular system
(IM,SC)4. Through natural orifices (rectal, nasal & vaginal)
![Page 5: BASIC PHARMACOKINETICS](https://reader035.fdocuments.in/reader035/viewer/2022081503/5681358c550346895d9cf3bc/html5/thumbnails/5.jpg)
ADMINISTRATION
Second category – drugs injected directly into the
systemic circulation (IV)
Third category – Topicals through skin (stratum corneum)
Fourth category – Drug administered by these specialized routes of administration achieve
local and targeted therapy. A portion may reach systemic circulations (SA. Epidural, intraocular)
![Page 6: BASIC PHARMACOKINETICS](https://reader035.fdocuments.in/reader035/viewer/2022081503/5681358c550346895d9cf3bc/html5/thumbnails/6.jpg)
![Page 7: BASIC PHARMACOKINETICS](https://reader035.fdocuments.in/reader035/viewer/2022081503/5681358c550346895d9cf3bc/html5/thumbnails/7.jpg)
ADMINISTRATION
1. Oral Administration• Most convenient, most economical • Disadvantages:
– emesis (drug irritation of the gastrointestinal mucosa)
– digestive enzymes/gastric acidity destroys the drug
– unreliable or inconsistent absorption due to food or other drug effects
– metabolism of the drug by gastrointestinal flora
![Page 8: BASIC PHARMACOKINETICS](https://reader035.fdocuments.in/reader035/viewer/2022081503/5681358c550346895d9cf3bc/html5/thumbnails/8.jpg)
• Factors determining rate of drug effect onset
1. Dissolution
2. Absorption
3. Significant first pass effects
4. The mucosal surface area
5. Gastric emptying
6. Perfusion to the gut mucosa
![Page 9: BASIC PHARMACOKINETICS](https://reader035.fdocuments.in/reader035/viewer/2022081503/5681358c550346895d9cf3bc/html5/thumbnails/9.jpg)
ADMINISTRATION2. Transdermal Administration• The delivery of drugs through an intact skin.• The stratum corneum is the main barrier to the
diffusion of drugs, especially polar compounds.• Potent drugs with high lipid solubility can be
absorbed transdermally to produce systemic effects (e.g. fentanyl, GTN, ethinylestradiol, hyoscine).
• The stratum corneum will also act as a reservoir for lipid soluble drugs for several days after the drug has been stopped.
![Page 10: BASIC PHARMACOKINETICS](https://reader035.fdocuments.in/reader035/viewer/2022081503/5681358c550346895d9cf3bc/html5/thumbnails/10.jpg)
![Page 11: BASIC PHARMACOKINETICS](https://reader035.fdocuments.in/reader035/viewer/2022081503/5681358c550346895d9cf3bc/html5/thumbnails/11.jpg)
Advantages: – sustained, therapeutic plasma levels
(reduced peaks/valleys associated with intermittent drug administrations)
– avoids continuous infusion technique difficulties
– low side effect incidence (smaller doses)
![Page 12: BASIC PHARMACOKINETICS](https://reader035.fdocuments.in/reader035/viewer/2022081503/5681358c550346895d9cf3bc/html5/thumbnails/12.jpg)
ADMINISTRATION
• Factors contributing to reliable transdermal drug absorption: – molecular weight < 1000 – pH range 5-9 in aqueous medium – no histamine-releasing action – daily drug requirement <10 mg
• Example of drugs available for transdermal delivery: fentanyl, GTN
![Page 13: BASIC PHARMACOKINETICS](https://reader035.fdocuments.in/reader035/viewer/2022081503/5681358c550346895d9cf3bc/html5/thumbnails/13.jpg)
ADMINISTRATION
3. Rectal Administration• Proximal rectum administration
Absorption into superior hemorrhoidal veins then enters the portal venous system then to the liver (possible first pass hepatic effect) and finally into the systemic circulation
• Low rectal administration of drug may allow the drug to enter the systemic circulation without passing through the liver
• Generally unpredictable pharmacological responses for the above reasons
• Rectal mucosal irritation possible
![Page 14: BASIC PHARMACOKINETICS](https://reader035.fdocuments.in/reader035/viewer/2022081503/5681358c550346895d9cf3bc/html5/thumbnails/14.jpg)
ADMINISTRATION4. INTRAMUSCULAR• Less painful than subcutaneous injection• Muscle less prone to chemical injury and infection
than SC fat• Irritating substances may be given• Uptake of drugs following IM injection is more
rapid, especially for water-soluble drugs• Duration of action shorter following IM than SC
injection.• Absorption is dependent on perfusion• Unpredictable in the very emaciated and obese• Complications – Sterile abscess, Sciatic nerve
injury, Pain
![Page 15: BASIC PHARMACOKINETICS](https://reader035.fdocuments.in/reader035/viewer/2022081503/5681358c550346895d9cf3bc/html5/thumbnails/15.jpg)
ADMINISTRATION4. SUBCUTANEOUS
• Advantages – absorption is slow and sustained
• Improve by i) hyaluronidase
ii) implanting insoluble pellets – contraceptive
iii) dissolving in oil – penicillin
• Time of onset – 30 mins, peak – 60 mins
• Skin blood flow – 12.8 ml/100g/min
• Decreases absorption when vasoconstricted
![Page 16: BASIC PHARMACOKINETICS](https://reader035.fdocuments.in/reader035/viewer/2022081503/5681358c550346895d9cf3bc/html5/thumbnails/16.jpg)
ADMINISTRATION5. INTRAVENOUS• No absorption required, bypass liver• Accurate and predictable• Fast: able to titrate in ill and old patient• Irritating substance may be used (endothelium relatively insensitive) Disadvantages
- No retreat- IV access required- Unfavourable reactions secondary to high plasma
concentration
![Page 17: BASIC PHARMACOKINETICS](https://reader035.fdocuments.in/reader035/viewer/2022081503/5681358c550346895d9cf3bc/html5/thumbnails/17.jpg)
ABSORPTION
Absorption : passage of a drug from an external site of administration across
body tissues to the systemic circulation / site of action. Absorption occurs through :
1. passive diffusion2. special carrier mechanism3. pinocytosis
![Page 18: BASIC PHARMACOKINETICS](https://reader035.fdocuments.in/reader035/viewer/2022081503/5681358c550346895d9cf3bc/html5/thumbnails/18.jpg)
Pinocytosis is the ingestion of dissolved materials by endocytosis. The cytoplasmic membrane invaginates and pinches off placing small droplets of fluid in a pinocytic vesicle. The liquid contents of the vesicle is then slowly transferred to the cytosol.
![Page 19: BASIC PHARMACOKINETICS](https://reader035.fdocuments.in/reader035/viewer/2022081503/5681358c550346895d9cf3bc/html5/thumbnails/19.jpg)
ABSORPTION
• Absorption occurs mainly by passive non-ionic diffusion and is therefore dependent on factors such as
1. Lipid solubility2. Molecular size3. Ionisation*
![Page 20: BASIC PHARMACOKINETICS](https://reader035.fdocuments.in/reader035/viewer/2022081503/5681358c550346895d9cf3bc/html5/thumbnails/20.jpg)
ABSORPTION
– Fick’s law of diffusion– Rate of diffusion A x D x (P1-P2)
T
» A = surface area» D = diffusion coefficient = solubility/ MW» T = thickness» P1-P2 = concentration gradient
![Page 21: BASIC PHARMACOKINETICS](https://reader035.fdocuments.in/reader035/viewer/2022081503/5681358c550346895d9cf3bc/html5/thumbnails/21.jpg)
ABSORPTION
![Page 22: BASIC PHARMACOKINETICS](https://reader035.fdocuments.in/reader035/viewer/2022081503/5681358c550346895d9cf3bc/html5/thumbnails/22.jpg)
IONIZATION• Drug ionization reduces a drug's ability to cross a
lipid bilayer• Amount of ionization depends on pKa (dissociation
constant)• Numerically equal to the pH of a solution in which
the drug is 50% ionised
• pKa of a drug is the measure of the acid strength, e.g. an acid with a pKa of 2 is 10X as strong as an acid with pKa of 3
• The basic strength of drugs increases with the pKa, a basic drug of pKa of 9 is 10X as strong as base with pKa of 8.
![Page 23: BASIC PHARMACOKINETICS](https://reader035.fdocuments.in/reader035/viewer/2022081503/5681358c550346895d9cf3bc/html5/thumbnails/23.jpg)
The equilibrium constant K is defined as the fraction of H+ and A- to the HA. K = ([H+] [A-] ) / [HA] for this equilibrium K is called Ka for acid dissociation constant.
Since we are interested in the amount of H+ we need to arrange the equation to just have [H+] in one side. [H+] = Ka ([HA]/[A-] )
Taking the logarithm of each side gives:log [H+] = log Ka + log ([HA]/[A-] )
Now we can multiple by -1.-log [H+] = -log Ka - log ([HA]/[A-] ) Which is the same as:-log [H+] = -log Ka + log ([A-] /[HA])
Traditionally, -log is substituted with a lower case p, so the equation becomes (known as the Henderson-Hasselback equation:
pH = pKa + log ([A-] /[HA])
![Page 24: BASIC PHARMACOKINETICS](https://reader035.fdocuments.in/reader035/viewer/2022081503/5681358c550346895d9cf3bc/html5/thumbnails/24.jpg)
So if we know the pH of a solution and the pKa we can determine how much [A-] and [HA] we have in solution, using the rearranged equation below.[A-] /[HA] = exp (pH - pKa)
This means that when pH is equal to pKa, [A-]
= [HA], or that the acid is 50% ionized.
pHpKa Ratio [A-] /[HA]
3 4 0.1
4 4 1
5 4 10
6 4 100
![Page 25: BASIC PHARMACOKINETICS](https://reader035.fdocuments.in/reader035/viewer/2022081503/5681358c550346895d9cf3bc/html5/thumbnails/25.jpg)
Ionization - Weak Acids
• eg Aspirin (pKa 3.5)• RCOOH RCOO- + H+
• pH = pKa + log [ionized]
[unionized]• Weak acid;
– >acidic; > unionized– >basic; >ionized
![Page 26: BASIC PHARMACOKINETICS](https://reader035.fdocuments.in/reader035/viewer/2022081503/5681358c550346895d9cf3bc/html5/thumbnails/26.jpg)
Ionization - Weak Bases
• eg Ephidrine (pKa 9.6)
• RNH3+ RNH2 + H+
• pH = pKa + log [unionized] [ionized]
• Weak base;– >basic; >unionized– >acidic; >ionized
![Page 27: BASIC PHARMACOKINETICS](https://reader035.fdocuments.in/reader035/viewer/2022081503/5681358c550346895d9cf3bc/html5/thumbnails/27.jpg)
![Page 28: BASIC PHARMACOKINETICS](https://reader035.fdocuments.in/reader035/viewer/2022081503/5681358c550346895d9cf3bc/html5/thumbnails/28.jpg)
Non-ionic diffusion of weak acid, pKa = 6
![Page 29: BASIC PHARMACOKINETICS](https://reader035.fdocuments.in/reader035/viewer/2022081503/5681358c550346895d9cf3bc/html5/thumbnails/29.jpg)
Non-ionic diffusion of weak base, pKa = 7
![Page 30: BASIC PHARMACOKINETICS](https://reader035.fdocuments.in/reader035/viewer/2022081503/5681358c550346895d9cf3bc/html5/thumbnails/30.jpg)
ION TRAPPING
• A phenomenon whereby drugs are kept in
environments of altered pH, by the change in equilibrium brought about
by the change in pH
![Page 31: BASIC PHARMACOKINETICS](https://reader035.fdocuments.in/reader035/viewer/2022081503/5681358c550346895d9cf3bc/html5/thumbnails/31.jpg)
![Page 32: BASIC PHARMACOKINETICS](https://reader035.fdocuments.in/reader035/viewer/2022081503/5681358c550346895d9cf3bc/html5/thumbnails/32.jpg)
Placental Transfer Of Basic Drugs
•e.g local anesthetics -fetal pH is lower than maternal pH -lipid-soluble, nonionized local anesthetic crosses the placenta converted to poorly lipid soluble ionized drug-gradient is maintained for continual transfer of local anesthetic from maternal circulation to fetal circulation-in fetal distress, acidosis contributes to local anesthetic accumulation
![Page 33: BASIC PHARMACOKINETICS](https://reader035.fdocuments.in/reader035/viewer/2022081503/5681358c550346895d9cf3bc/html5/thumbnails/33.jpg)
• Kidney - Nearly all drugs filtered at the glomerulus - Most drugs in a lipid-soluble form will be
reabsorbed by passive diffusion. - To increase excretion: change the urinary pH to
favor the charged form of the drug since charged form cannot be readily reabsorbed (they cannot readily pass through biological membranes)
– Weak acids: excreted faster in alkaline pH (anion form favored)
– Weak bases: excreted faster in acidic pH (cation form favored)
![Page 34: BASIC PHARMACOKINETICS](https://reader035.fdocuments.in/reader035/viewer/2022081503/5681358c550346895d9cf3bc/html5/thumbnails/34.jpg)
Bioavailability
• The proportion of intact/unchanged drug that is available to the systemic circulation, after oral/intramuscular administration.
• Affected by:– Extent of absorption– First Pass metabolism
![Page 35: BASIC PHARMACOKINETICS](https://reader035.fdocuments.in/reader035/viewer/2022081503/5681358c550346895d9cf3bc/html5/thumbnails/35.jpg)
Bioavailability = AUCPO X 100%
AUCIV
PO
IV
Quantifies Absorption
![Page 36: BASIC PHARMACOKINETICS](https://reader035.fdocuments.in/reader035/viewer/2022081503/5681358c550346895d9cf3bc/html5/thumbnails/36.jpg)
First Pass Metabolism• Proportion of drug that is removed or
metabolised by an organ before it reaches the systemic circulation during the initial single transit– Liver
• High ER (>0.7) eg Propanolol, Lignocaine• Low ER (<0.3) eg Warfarin, Thiopentone
– Gastrointestinal eg; L-dopa, Chlorpromazine– Pulmonary eg; Lignocaine, Propanolol,
opiods
![Page 37: BASIC PHARMACOKINETICS](https://reader035.fdocuments.in/reader035/viewer/2022081503/5681358c550346895d9cf3bc/html5/thumbnails/37.jpg)
DISTRIBUTION
• After gaining access to the systemic circulation, drugs distribute in different tissues and organs of the body.
• Factors affecting;– Physicochemical char. of the drugs
• Lipid solubility• Degree of ionization
– Cardiac output & regional blood flow to various organs: VRG, MG, FG
– Binding: Plasma protein / Tissues
![Page 38: BASIC PHARMACOKINETICS](https://reader035.fdocuments.in/reader035/viewer/2022081503/5681358c550346895d9cf3bc/html5/thumbnails/38.jpg)
Volume of Distribution• Quantifies distribution.• Volume of distribution (Vd) of a drug is a
mathematical expression of the sum of the apparent volumes of the compartments that constitute the compartmental model.
• This value depicts the distribution characteristics of a drug in the body.
• The volume in which the amount of drug in the body would need to be uniformly distributed to produce the observed plasma concentration.
![Page 39: BASIC PHARMACOKINETICS](https://reader035.fdocuments.in/reader035/viewer/2022081503/5681358c550346895d9cf3bc/html5/thumbnails/39.jpg)
• Volume of distribution is calculated as the dose of drug administered intravenously divided by the resulting plasma concentration of drug before elimination starts.
Vd = Amount of Drug in the Body Plasma Drug Concentration
• Indicates the extent of extravascular tissue uptake of the drugs
![Page 40: BASIC PHARMACOKINETICS](https://reader035.fdocuments.in/reader035/viewer/2022081503/5681358c550346895d9cf3bc/html5/thumbnails/40.jpg)
Volume of DistributionFactors determining Vd1. Physicochemical characteristics of the drug
– Lipid solubility of drug– Degree of ionisation (function of drug
pKa and ambient pH)
– Molecular weight2. Degree of plasma protein binding (acidic
and neutral drugs to albumin and basic drugs to 1-acid glycoprotein)3. Tissue binding4. Regional blood flow to tissues (affected by
age and disease states eg CRF, CCF)
![Page 41: BASIC PHARMACOKINETICS](https://reader035.fdocuments.in/reader035/viewer/2022081503/5681358c550346895d9cf3bc/html5/thumbnails/41.jpg)
Volume of DistributionClinical Significants
Drugs with small Vd (5-20 litres) are predominantly localized in plasma/ECF (muscle relaxants) or are extensively bound to plasma proteins (warfarin, phenytoin, tolbutamide). These are typically highly polar, water-soluble drugs.
Drugs with Vd equal to TBW (30-45 L in adults) are evenly distributed throughout TBW (examples are alcohol, urea and some sulphonamides)
Drugs with Vd larger than TBW have extensive tissue penetration and binding to tissues or sequestration in fats. In these circumstances, the concentration in tissues may be higher than in plasma. These are typically highly lipid soluble drugs for example digoxin, fentanyl, thiopentone, most phenothiazines a most anti-depressants.
![Page 42: BASIC PHARMACOKINETICS](https://reader035.fdocuments.in/reader035/viewer/2022081503/5681358c550346895d9cf3bc/html5/thumbnails/42.jpg)
![Page 43: BASIC PHARMACOKINETICS](https://reader035.fdocuments.in/reader035/viewer/2022081503/5681358c550346895d9cf3bc/html5/thumbnails/43.jpg)
Protein Binding
• Drugs are bound to plasma protein in a reversible
manner• Saturable process• 3 main types of carrier proteins for drugs:
1. Albumin – bound mainly to acidic drugs e.g diazepam, digoxin, warfarin, barbiturates2. α1-acid glycoprotein – bound mainly to basic
drugs e.g. opioids, β-Blockers, Tricyclic anti-
depressants, LA, antiarrhythmics3. Globulins – Steroid hormones, Thyroid hormone
![Page 44: BASIC PHARMACOKINETICS](https://reader035.fdocuments.in/reader035/viewer/2022081503/5681358c550346895d9cf3bc/html5/thumbnails/44.jpg)
Protein Binding
• fraction unbound (fU) = unbound [drug] total [drug]
• fU is determined by
i) The affinity of the drug for proteinii) The concentration of the binding
proteiniii) The concentration of the drug
relative to that of binding protein
![Page 45: BASIC PHARMACOKINETICS](https://reader035.fdocuments.in/reader035/viewer/2022081503/5681358c550346895d9cf3bc/html5/thumbnails/45.jpg)
Protein BindingImplication1. Distribution2. Clearance - bound and free drug can be cleared by liver and kidney
- in liver, ↑ ER (> 0.7) insensitive to protein binding
but for ↓ ER (<0.3), dependent on [free drug] - in kidney, glomerular filtration dependent on
protein binding3. Disease Process - altered in renal or liver diseases4. Drug interaction
![Page 46: BASIC PHARMACOKINETICS](https://reader035.fdocuments.in/reader035/viewer/2022081503/5681358c550346895d9cf3bc/html5/thumbnails/46.jpg)
METABOLISM
• Role of metabolism or biotransformation is to convert pharmacologically active, lipid-soluble drugs into water soluble and often pharmacologically inactive metabolites.
• Increased water solubility decreases the Vd and enhance its excretion.
• Main site liver, others are kidney, lung, plasma
• Drug biotransformation mechanisms are described as either phase I or phase II reaction types.
![Page 47: BASIC PHARMACOKINETICS](https://reader035.fdocuments.in/reader035/viewer/2022081503/5681358c550346895d9cf3bc/html5/thumbnails/47.jpg)
Phase I Metabolism (non synthetic reactions)
• Usually result in drug oxidation, reduction or hydrolysis.
• Most phase 1 reactions are carried out by the liver cell in the smooth ER or microsomes
• A non-specific enzyme system in the ER (Cytochrome P-450 or mixed function oxidase system) is responsible for most drug oxidations and reductions and for some hydrolytic reactions
![Page 48: BASIC PHARMACOKINETICS](https://reader035.fdocuments.in/reader035/viewer/2022081503/5681358c550346895d9cf3bc/html5/thumbnails/48.jpg)
Cytochrome 450 System
oxidation-reduction process
Involves two important microsomal enzymes
1. Cytochrome P450
2. Flavoprotein
Gain of electron (e-) result in reduction
Loss of e- results in oxidation
InduceInhibited
Inactivated
![Page 49: BASIC PHARMACOKINETICS](https://reader035.fdocuments.in/reader035/viewer/2022081503/5681358c550346895d9cf3bc/html5/thumbnails/49.jpg)
Phase II metabolism (synthetic or conjugation reactions)
• Combinaton of unchanged drugs or phase I metabolites with other chemical group (eg; glucuronide, sulphate, acetate etc)
• The most important reaction is conjugation of drugs to glucuronides
• Conjugates are often polar and inactive
• Occurs both in microsomes or cytosol
![Page 50: BASIC PHARMACOKINETICS](https://reader035.fdocuments.in/reader035/viewer/2022081503/5681358c550346895d9cf3bc/html5/thumbnails/50.jpg)
Phase II Metabolism
Adapted from Table 4-3, Correia, M.A., Drug Biotransformation. in Basic and Clinical Pharmacology, (Katzung, B. G., ed) Appleton-Lange, 1998, p 57.
Some Phase II Reactions
Type of Conjugation Endogenous Reactant Transferase (Location) Types of Substrates Examples
Glucuronidation UDP glucuronic acidUDP glucuronosyl transferase
(microsomal)
phenols, alcohols, carboxylic acids, hydroxylamines,
sulfonamides
morphine, acetaminophen, diazepam, digitoxin,
digoxin, meprobamate
Acetylation Acetyl-CoA N-Acetyl transferase (cytosol) Aminessulfonamides, isoniazid,
clonazepam, dapsone, mescaline
Glutathione conjugation glutathioneGSH-S-transferase (cytosolic,
microsomes)epoxides, nitro groups,
hydroxylaminesethycrinic acid, bromobenzene
Sulfate conjugationPhosphoadenosyl
phosphosulfateSulfotransferase (cytosol)
phenols, alcohols, aromatic amines
estrone, 3-hydroxy coumarin, acetaminophen,
methyldopa
Methylation S-Adenosyl-methionine transmethylases (cytosol)catecholamines, phenols,
amines, histamine
dopamine, epinephrine, histamine, thiouracil,
pyridine
![Page 51: BASIC PHARMACOKINETICS](https://reader035.fdocuments.in/reader035/viewer/2022081503/5681358c550346895d9cf3bc/html5/thumbnails/51.jpg)
METABOLISM
Rate of metabolism is determined by:• drug concentration at the site of
metabolism• Intrinsic rate of metabolism process
(enzyme activity)
Rate of metabolism best described by first-order
and zero-order kinetics.
![Page 52: BASIC PHARMACOKINETICS](https://reader035.fdocuments.in/reader035/viewer/2022081503/5681358c550346895d9cf3bc/html5/thumbnails/52.jpg)
First-Order Kinetics
Definition•A constant percentage of drug is eliminated from the body per unit time.•As the drug concentration increases, proportionally more drug is removed. •Fraction of drug metabolized is independent of concentration •Elimination half-life remains constant •Most drugs obey first order kinetics
![Page 53: BASIC PHARMACOKINETICS](https://reader035.fdocuments.in/reader035/viewer/2022081503/5681358c550346895d9cf3bc/html5/thumbnails/53.jpg)
![Page 54: BASIC PHARMACOKINETICS](https://reader035.fdocuments.in/reader035/viewer/2022081503/5681358c550346895d9cf3bc/html5/thumbnails/54.jpg)
ZERO ORDER KINETICS Definition
• A constant amount of drug is eliminated from the body per unit time. Also known as Michaelis Menten Kinetics
• Occurs when [drug] exceeds capacity of enzymes (saturated)
• Intrinsic activity of enzymes determines the amount of drug metabolised
• Aspirin, theophylline and warfarin examples for drugs that follow zero order at normal doses (higher doses → thiopentone)
![Page 55: BASIC PHARMACOKINETICS](https://reader035.fdocuments.in/reader035/viewer/2022081503/5681358c550346895d9cf3bc/html5/thumbnails/55.jpg)
ZERO ORDER KINETICS
Enzymes are no longer saturated therefore drugs undergo 1st order kinetics
![Page 56: BASIC PHARMACOKINETICS](https://reader035.fdocuments.in/reader035/viewer/2022081503/5681358c550346895d9cf3bc/html5/thumbnails/56.jpg)
![Page 57: BASIC PHARMACOKINETICS](https://reader035.fdocuments.in/reader035/viewer/2022081503/5681358c550346895d9cf3bc/html5/thumbnails/57.jpg)
CLEARANCE
• Volume of blood which is irreversibly cleared of a substance per unit time.
• Quantifies elimination
Clsystemic = Clhepatic + Clrenal + Clothers
![Page 58: BASIC PHARMACOKINETICS](https://reader035.fdocuments.in/reader035/viewer/2022081503/5681358c550346895d9cf3bc/html5/thumbnails/58.jpg)
CLEARANCE
• Two physiological variables control the
clearance:i) Efficiency of the eliminating organ ii) Blood flow to the organ
![Page 59: BASIC PHARMACOKINETICS](https://reader035.fdocuments.in/reader035/viewer/2022081503/5681358c550346895d9cf3bc/html5/thumbnails/59.jpg)
ELIMINATION
Sites– Renal– Hepatobiliary– Pulmonary– Saliva– Sweat– Breast milk– Tears– Vaginal secretions– GIT
![Page 60: BASIC PHARMACOKINETICS](https://reader035.fdocuments.in/reader035/viewer/2022081503/5681358c550346895d9cf3bc/html5/thumbnails/60.jpg)
RENAL CLEARANCE
• Most low MW compounds and their metabolites are excreted in urine
• When total clearance is predominantly by renal (ClR > 0.7), accumulation will occur in renal failure e.g aminoglycosides, digoxin
• If ClR < 0.3, renal disease have little effect on drug elimination
![Page 61: BASIC PHARMACOKINETICS](https://reader035.fdocuments.in/reader035/viewer/2022081503/5681358c550346895d9cf3bc/html5/thumbnails/61.jpg)
RENAL HANDLING OF DRUGSThe renal elimination of drugs is dependent onthree separate processes that take place atdifferent sites of the nephron:
1. Glomerular Filtration 2. Active Tubular Secretion3. Distal Tubular Reabsorption
![Page 62: BASIC PHARMACOKINETICS](https://reader035.fdocuments.in/reader035/viewer/2022081503/5681358c550346895d9cf3bc/html5/thumbnails/62.jpg)
GLOMERULAR FILTRATION
• Only the free or unbound fraction in plasma
water is available for filtration by the renal
glomerulus.
• Affected by drug molecular size,
electrical charge of drug molecule and the
number of functioning nephrons present.
![Page 63: BASIC PHARMACOKINETICS](https://reader035.fdocuments.in/reader035/viewer/2022081503/5681358c550346895d9cf3bc/html5/thumbnails/63.jpg)
ACTIVE TUBULAR SECRETION• Active secretion of drugs by the
proximal tubules occurs via an active carrier transport mechanism→ requires cellular energy and may go against concentration gradient.
• So active with some drugs that even bound drugs can be stripped of plasma proteins in one pass of the blood.
• Dependent on renal perfusion.
• Independent of protein binding.
![Page 64: BASIC PHARMACOKINETICS](https://reader035.fdocuments.in/reader035/viewer/2022081503/5681358c550346895d9cf3bc/html5/thumbnails/64.jpg)
ACTIVE TUBULAR SECRETION• Acidic and basic drugs are secreted by 2
separate and distinct transport systems.
• Acidic drugs may compete with each other for tubular secretion; conversely basic drugs may interfere with the elimination of other bases or cations.
• Examples are:
Acidic drugs: penicillins, cephalosporins, salicylates,
thiazide diuretics, furosemide
Basic drugs: dopamine, morphine, neostigmine,
lignocaine
![Page 65: BASIC PHARMACOKINETICS](https://reader035.fdocuments.in/reader035/viewer/2022081503/5681358c550346895d9cf3bc/html5/thumbnails/65.jpg)
PASSIVE TUBULAR REABSORPTION
• In the distal renal tubules passive reabsorption of drugs occurs by non-ionic diffusion.
• The urine here is normally acidic, but can range from pH 4.5 to 8.0, and therefore a considerate gradient of H+ exists between urine and plasma.
• Drugs secreted at prox. tubules are ionised form. As urine becomes > acidic, acidic drugs will exist in non ionised form and can readily diffuse back into plasma → ↓ elimination
![Page 66: BASIC PHARMACOKINETICS](https://reader035.fdocuments.in/reader035/viewer/2022081503/5681358c550346895d9cf3bc/html5/thumbnails/66.jpg)
PASSIVE TUBULAR REABSORPTION
• Dependent on - Urine pH determines non-ionized
fraction in urine - Flow rate through the tubules
determines transit time and concentration gradient developed in tubules• Weak acids are excreted more rapidly in
alkaline urine.
• Alkalinization result more ionized drug and resulting less passive reabsorption of the drug.
![Page 67: BASIC PHARMACOKINETICS](https://reader035.fdocuments.in/reader035/viewer/2022081503/5681358c550346895d9cf3bc/html5/thumbnails/67.jpg)
DRUGS WITH CLINICALLY IMPORTANT URINE PH-DEPENDENT ELIMINATION
Weak acids (Alkaline urine increases excretion):
Phenobarbitone Salicylates
Sulphonamide derivatives
Weak bases (Acid urine increases excretion): Amphetamine
Ephedrine Quinine
![Page 68: BASIC PHARMACOKINETICS](https://reader035.fdocuments.in/reader035/viewer/2022081503/5681358c550346895d9cf3bc/html5/thumbnails/68.jpg)
DOSE ADJUSTMENT IN RENAL DYSFUNCTION
• Renal clearance is reduced in proportion with the reduction in creatinine clearance.
• Adjustment is usually only necessary when a drug is more than 50% cleared by renal elimination and when renal function is reduced to half of normal or less.Creatinine Clearance = (140 – Age) X
Weight X constant
(Cockcroft Gault) Serum Creatinine (mol/L)
(Constant = 1.23 for men , 1.04 for female)
![Page 69: BASIC PHARMACOKINETICS](https://reader035.fdocuments.in/reader035/viewer/2022081503/5681358c550346895d9cf3bc/html5/thumbnails/69.jpg)
HEPATIC CLEARANCE
• At steady state, the removal of drugs by the liver can be expressed by the extraction ratio (ER).
• extraction ratio is an overall measure of the ability of the liver to remove drugs from the hepatic capillaries and reflects drug metabolism.
ER = Ca – Cv Ca where
Ca = [drug] in mixed portal venous and hepatic arterial blood
Cv = [drug] in hepatic venous blood.
![Page 70: BASIC PHARMACOKINETICS](https://reader035.fdocuments.in/reader035/viewer/2022081503/5681358c550346895d9cf3bc/html5/thumbnails/70.jpg)
HEPATIC CLEARANCE
![Page 71: BASIC PHARMACOKINETICS](https://reader035.fdocuments.in/reader035/viewer/2022081503/5681358c550346895d9cf3bc/html5/thumbnails/71.jpg)
HEPATIC CLEARANCE
Hepatic clearance is dependent on 3 biologic
factors:
1. Hepatic blood flow
2. Intrinsic metabolising capacity of the
liver (reflects the activity of drug
metabolising enzymes)
3. The proportion of unbound drug in blood,
which is affected by plasma drug binding.
![Page 72: BASIC PHARMACOKINETICS](https://reader035.fdocuments.in/reader035/viewer/2022081503/5681358c550346895d9cf3bc/html5/thumbnails/72.jpg)
INTRINSIC HEPATIC CLEARANCE • Represents the rate at which liver water is cleared of
drug in ml/min.
• Represents the maximum ability of the liver to irreversibly eliminate drugs by metabolism or biliary excretion.
• Is independent of liver blood flow.
• ClH = Q x ClI x fU
Q + (ClI x fU)
ClI = intrinsic hepatic clearance
fU = fraction of unbound drug
![Page 73: BASIC PHARMACOKINETICS](https://reader035.fdocuments.in/reader035/viewer/2022081503/5681358c550346895d9cf3bc/html5/thumbnails/73.jpg)
FLOW OR PERFUSION LIMITED DRUGS
• When intrinsic hepatic clearance is high relative to HBF, then hepatic clearance determined by liver blood flow.
• Most of drug is extracted by liver on one passage high ER (> 0.7).
• NOT affected by protein binding or enzyme activity level.
• First pass effect is high.
• Sensitive only to factors that affect hepatic blood flow.
• Examples are lignocaine, tricyclic antidepressants, opioids and some ß-blockers.
![Page 74: BASIC PHARMACOKINETICS](https://reader035.fdocuments.in/reader035/viewer/2022081503/5681358c550346895d9cf3bc/html5/thumbnails/74.jpg)
ENZYME LIMITED DRUGS (CAPACITY LIMITED)
• When intrinsic hepatic clearance is low relative to HBF.
• Low ER (i.e. < 0.3); hepatic clearance is dependent on intrinsic clearance (i.e. enzyme activity) and the fraction of drug unbound in blood.
• Sensitive to liver enzyme activity profoundly affected by enzyme induction or inhibition.
• Hepatic clearance NOT affected by changes to HBF.
• Low first pass effect after oral administration.
• Examples are phenytoin, warfarin, theophylline, most barbiturates and benzodiazepines.
![Page 75: BASIC PHARMACOKINETICS](https://reader035.fdocuments.in/reader035/viewer/2022081503/5681358c550346895d9cf3bc/html5/thumbnails/75.jpg)
ENZYME LIMITED DRUGS (CAPACITY LIMITED)
• Enzyme limited, binding insensitiveDrugs with low binding to plasma proteins (< 20-30%) may be unaffected by changes in protein binding
• Enzyme limited, binding sensitiveDrugs that are extensively bound to plasma proteins (> 85%), hepatic clearance will be affected by changes in protein binding.
![Page 76: BASIC PHARMACOKINETICS](https://reader035.fdocuments.in/reader035/viewer/2022081503/5681358c550346895d9cf3bc/html5/thumbnails/76.jpg)
BILIARY EXCRETION OF DRUGS
• Biliary excretion is usually the major route of elimination for compounds with MW > 400-500 Da.
• This active mechanism via Na/K/ATPase transport system is able to concentrate drugs to even 100 times their plasma levels.
• Drugs with high clearance in bile
- Acidic drugs: ampicillin, rifampicin, radiographic
contrast
- Basic drugs: Vecuronium, pancuronium, alcuronium,
glycopyrrolate
![Page 77: BASIC PHARMACOKINETICS](https://reader035.fdocuments.in/reader035/viewer/2022081503/5681358c550346895d9cf3bc/html5/thumbnails/77.jpg)
CLEARANCE: CLINICAL USAGE1. One of the determinants of half-life.
t½ = 0.693 Vd
Cl 2. Determines the amount of drug needed to for
maintenancedose.
Elimination Rate = Clearance X Plasma Concentration
Steady state is defined as the situation at which the rate of drug
administration is equal to the rate of drug elimination so that plasma drug concentration remains equal.
Therefore, Elimination Rate = Maintenance Rate Maintenance Dose = Clearance X Desired Cpss
![Page 78: BASIC PHARMACOKINETICS](https://reader035.fdocuments.in/reader035/viewer/2022081503/5681358c550346895d9cf3bc/html5/thumbnails/78.jpg)
HALF-LIFE (t½)
• Half-life is the time taken for the plasma concentration to fall by half its initial value.
• Depends on clearance and volume of distribution.
• 1 t ½ = 50% elimination 2 t ½ = 75% elimination 3 t ½ = 87.5% elimination 4 t ½ = 93.75% elimination → requires 4-5 half lives to eliminate drug
![Page 79: BASIC PHARMACOKINETICS](https://reader035.fdocuments.in/reader035/viewer/2022081503/5681358c550346895d9cf3bc/html5/thumbnails/79.jpg)
FACTORS AFFECTING T½
• t1/2 = 0.693 Vd Cl• An in the t½ may be due to Vd or Cl• Differentiating the primary change is
important as one will require increasing loading dose while the other requires lowering dosing rate
a. Decrease dose (smaller Vd)b. Increase dosing interval (decreased clearance)c. Reduce infusion rate (decreased clearance)
![Page 80: BASIC PHARMACOKINETICS](https://reader035.fdocuments.in/reader035/viewer/2022081503/5681358c550346895d9cf3bc/html5/thumbnails/80.jpg)
CLINICAL APPLICATIONS T½
• Predicts time taken to reach steady-state conditions following initiation of therapy (4-5 half lives).
• Predicts time taken for attainment of new steady state following increase or decrease of drug dose
• Determines the dosing interval• Predicts time taken for termination
of drug effect in some drugs
![Page 81: BASIC PHARMACOKINETICS](https://reader035.fdocuments.in/reader035/viewer/2022081503/5681358c550346895d9cf3bc/html5/thumbnails/81.jpg)
CONTEXT-SENSITIVE HALF-TIME
• Context-sensitive half-time, in contrast to elimination half-time, considers the combined effects of distribution and metabolism as well as duration of continuous IV administration on drug pharmacokinetics.
• Depending largely on the lipid solubility of the drug and the efficiency of its clearance mechanisms, the context-sensitive half-time increases in parallel with the duration of continuous IV administration
![Page 82: BASIC PHARMACOKINETICS](https://reader035.fdocuments.in/reader035/viewer/2022081503/5681358c550346895d9cf3bc/html5/thumbnails/82.jpg)
![Page 83: BASIC PHARMACOKINETICS](https://reader035.fdocuments.in/reader035/viewer/2022081503/5681358c550346895d9cf3bc/html5/thumbnails/83.jpg)
COMPARTMENT MODEL
Why Model Data?♦ A successful model allows one to
summarize large amounts of data into a few values that describe the whole data set.
♦ Allows us to make prediction and therefore calculate dose regimens
![Page 84: BASIC PHARMACOKINETICS](https://reader035.fdocuments.in/reader035/viewer/2022081503/5681358c550346895d9cf3bc/html5/thumbnails/84.jpg)
Compartment Models• One Compartment Model
– Distributed into a single compartment in the body
– From which a constant proportion of drug in the body is eliminated within a specific time period
compartmentDrug Dose
Elimination
![Page 85: BASIC PHARMACOKINETICS](https://reader035.fdocuments.in/reader035/viewer/2022081503/5681358c550346895d9cf3bc/html5/thumbnails/85.jpg)
![Page 86: BASIC PHARMACOKINETICS](https://reader035.fdocuments.in/reader035/viewer/2022081503/5681358c550346895d9cf3bc/html5/thumbnails/86.jpg)
Compartment Models
• Two Compartmental Model– Following administration, the drug is
rapidly distributed in the central compartment and then slowly equilibrates with another(peripheral) compartment
• 2 distinct phases;– Distribution phase– Elimination phase
![Page 87: BASIC PHARMACOKINETICS](https://reader035.fdocuments.in/reader035/viewer/2022081503/5681358c550346895d9cf3bc/html5/thumbnails/87.jpg)
Drug Dose
Elimination ()
Distribution ()
Central compartment
Peripheral compartment
Represented by intravascular fluids and highly prefused organs
![Page 88: BASIC PHARMACOKINETICS](https://reader035.fdocuments.in/reader035/viewer/2022081503/5681358c550346895d9cf3bc/html5/thumbnails/88.jpg)
![Page 89: BASIC PHARMACOKINETICS](https://reader035.fdocuments.in/reader035/viewer/2022081503/5681358c550346895d9cf3bc/html5/thumbnails/89.jpg)
Compartment Models3 Compartment Models
![Page 90: BASIC PHARMACOKINETICS](https://reader035.fdocuments.in/reader035/viewer/2022081503/5681358c550346895d9cf3bc/html5/thumbnails/90.jpg)
• After IV injection of some drugs, the initial rapid distribution is followed by a second slower distribution phase before the elimination phase
• The decline in the plasma concentration of many opioid drugs, muscle relaxants and IV anaesthetics can be resolved into three components
• Drug is injected into and eliminated from central compartment and reversibly transferred between central and two peripheral compartments
![Page 91: BASIC PHARMACOKINETICS](https://reader035.fdocuments.in/reader035/viewer/2022081503/5681358c550346895d9cf3bc/html5/thumbnails/91.jpg)
THE END